Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118689
Title Alternative
Efficacy and safety of radionuclide-labeled peptide therapy (PRRT) in four patients with unresectable or recurrent pancreatic neuroendocrine tumor (NETG2)
P-NETG2に対しPRRTを施行した4例に関する検討
Author
Nakanishi, Hayato Tokushima University
Hirata, Keiichiro Tokushima University
Miyake, Takanori Tokushima University
Yoshimoto, Takanori Tokushima University
Wada, Hironori Tokushima University
Kasai, Yoshihito Tokushima University
Keywords
NET PRRT
Content Type
Journal Article
Description
In June 2021, 177Lu-oxodotreotide, a PRRT, was approved by insurance for unresectable or recurrent NETs. We investigated the efficacy and safety of PRRT in four patients with P-NETs at our hospital. All patients were confirmed to be positive for somatostatin receptors by using octreoscan. PRRT treatment was then performed and retrospectively evaluated for efficacy and safety. PRRT was administered as lutetium oxodotreotide(177Lu) at 7.4 GBq per dose over 30 - minutes for up to 1 - 4 doses at 8 - week intervals. Efficacy was evaluated using RECIST v1. 1. Adverse effects were evaluated by CTCAE(v5.0 JCOG).
The mean patient age was 60±12.0 years, and all patients were male. Three patients had a PS of 0, and one patient had a PS of 1 or higher. Metastatic organs were the liver in four patients and intra-abdominal lymph nodes in one patient, all of whom were Stage IV. Three patients underwent transarterial embolization. 177Lu-DOTATOC PRRT was administered every 8 weeks, and a total of four courses were administered in two patients, three courses in one patient, and one course in one patient. One patient had grade 2 thrombocytopenia after one course, and the second course was administered at a half dose(3.7 GBq). The overall response rate(ORR) was 25%, with one PR and two SD. The median PFS was 9 months(95% Cl, 8-NA), and the median overall survival from diagnosis was 119 months(95%Cl, 31 - NA). Adverse events during PRRT included leukopenia in two patients(one G3, one G2), lymphopenia in one patient(one G3), thrombocytopenia in two patients(two G2, one G3), creatinine increase in one patient(one G2), and skin rash in one patient.
In conclusion, PRRT is expected to be highly effective and safe compared with conventional therapy for neuroendocrine tumors with unresectable or distant metastases.
Journal Title
Shikoku Acta Medica
ISSN
27583279
Publisher
徳島医学会
Volume
79
Issue
3-4
Start Page
181
End Page
186
Sort Key
181
Published Date
2023-09-27
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
jpn
TextVersion
Publisher
departments
University Hospital
Medical Sciences